GlassScriptPhysician profile
James Fagin
NPI 1447344577
$686.50
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $404.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $168.37 | 2019-2020 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Pfizer INC. | $49.90 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.99 | 2020 | |
| Kaleo, INC. | $43.37 | 2019-2020 | |
| Pharming Healthcare, INC. | $37.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $36.98 | 2019-2020 | |
| Octapharma USA, INC. | $33.12 | 2020 | |
| Grifols USA, LLC | $31.19 | 2020 | |
| Covis Pharma Gmbh | $23.34 | 2020 | |
| Bio Products Laboratory USA, INC. | $21.46 | 2019 | |
| Aimmune Therapeutics, INC. | $17.77 | 2020 | |
| Horizon Therapeutics Plc | $15.87 | 2020 | |
| Csl Behring | $14.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.47 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $11.46 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fagin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.